Crossmark

Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer

Crossref DOI link: https://doi.org/10.1080/21645515.2024.2379864

Published Online: 2024-08-20

Published Print: 2024-12-31

Update policy: https://doi.org/10.1080/tandf_crossmark_01

Authors

Wiseman, Charles L.

Holmes, Jarrod P.

Calfa, Carmen

Dakhil, Shaker R.

Bhattacharya, Saveri

Peoples, George E.

Lacher, Markus D. https://orcid.org/0000-0003-2597-5704
Lopez-Lago, Miguel

Kharazi, Alex

Del Priore, Giuseppe

Chang, Mingjin

Adams, Daniel L. https://orcid.org/0000-0002-1916-9637
Williams, William V. https://orcid.org/0000-0003-3611-9284
Funding

Funding for this research was provided by:

BriaCell Therapeutics Corp
License Information

Version of Record valid from 2024-08-20
More Information

Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.

Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=khvi20

Publication History

Received: 2024-03-01

Revised: 2024-07-01

Accepted: 2024-07-10

Published: 2024-08-20